TA84

Sepsis (severe) - drotrecogin (withdrawn) (TA84)

  • Technology appraisals TA84
  • Issued: September 2004
    • Drotrecogin alpha (activated) for severe sepsis

      Drotrecogin alfa (activated) is recommended for adult patients who

      • have severe sepsis that has resulted in multiple organ failure (two or more major organs are not working properly) and
      • are being given the most appropriate intensive care support for their condition.

      The use of drotrecogin alfa (activated) should be started and supervised by a specialist consultant with skills in intensive care and experience in the care of patients with sepsis.

      • Drotrecogin alpha (activated) for severe sepsis: withdrawal of product following recent clinical trial results

        On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris(R) [drotrecogin alfa (activated)] product in all markets following results of the PROWESS-SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying health care professionals and clinical trial investigators.

        As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alpha (activated) for severe sepsis.

      • Other information

        How this guidance was produced

        Background information

        • None found

      This page was last updated: 10 November 2011

    • Guidance formats

      Query

Implementation tools and resources

  • None available

See this guidance in practice

Patient

The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.

Quick Reference Guide

The quick reference guide presents recommendations for health professionals

NICE Guidance

The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.

Full Guidance

The published full clinical guidance for specialists with background, evidence, recommendations and methods used.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.